Drug intelligence / Profile preview

MT303

Development stage: Preclinical
Lead developer: Myeloid Therapeutics
Administration: Intravenous

Overview

**MT303** is a preclinical inflammatory bowel disease candidate developed by Mthera Pharma. It was listed in Mthera Pharma's pipeline as an asset developed using the company's proprietary Multi-Component Multi-Target platform. The active constituents, molecular targets, pharmacologic modality, route of administration, dosage form, and detailed mechanism of action have not been publicly disclosed for this specific Mthera Pharma asset.

Targets

GPC3 (Glypican-3)

Beyond the preview

Go deeper on MT303.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT303.

Explore the full profile